HOME >> BIOLOGY >> NEWS
Boat paint to blame for Norfolk Broads' desolation

One of the main culprits behind an environmental catastrophe that desolated one of Britain's most important wildlife habitats has finally been identified in a study led by researchers from UCL (University College London) and Acroloxus Wetlands Consultancy Ltd, Canada.

In the current issue of the journal Environmental Science & Technology, they reveal that introduction of the compound tributyltin (TBT) as a biocide in boat paint in the 1960s resulted in a dramatic and sudden loss of aquatic vegetation from most of the 50 or so Norfolk Broads lakes.

At the time, scientists pointed the finger at contamination from sewage works and fertiliser run-off from farmland, despite suggestions from the local community that the burgeoning leisure boating industry might be to blame.

Though the use of TBT was banned in freshwater systems in the UK in 1987, the researchers say 40 years on from TBT's introduction the fragile ecosystem remains shattered despite expensive attempts to restore it.

Dr Carl Sayer, of the UCL Environmental Change Research Centre, who co-led the study, says: "For too long TBT has been neglected as a driver of environmental destruction in freshwater wetlands and even though it is no longer in use in UK inland waterways, TBT contamination and its negative effects are still being reported all over the world.

"Real concerns have been raised about TBT derived from industrial and ship breaking activities in several major river systems including the Ganges, Brahmaputra and Yangtze all of which are connected to shallow lakes. In the case of the Yangtze, the linked shallow lakes are some of the largest in the world and, like the Broads, have experienced problems with plant loss on a large scale."

TBT was originally designed for use on the hulls of large ocean-going ships to reduce the build-up of barnacles. Since the 1970s it has been linked to a host of negative effects in the marine environment includ
'"/>

Contact: Judith H Moore
judith.moore@ucl.ac.uk
44-020-767-97678
University College London
18-Sep-2006


Page: 1 2

Related biology news :

1. Tumor painting revolutionizes fight against cancer
2. Engineers develop process to recycle unused paint by blending it into common plastics
3. Ancient war paint in fight against breast cancer
4. Study supports urgent need for worldwide ban on lead-based paint
5. Shampoo detergent added to paint makes surfaces self-sterilizing
6. In anoxia, why cant humans be more like western painted turtles?
7. Chemical used in marine paint may damage hearing in whales
8. Metabolic syndrome -- dont blame the belly fat
9. Bone and cartilage growth to blame for heart valve disease
10. Global warming - the blame is not with the plants
11. How do you feel? Genetics are partly to blame

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Boat paint blame for Norfolk Broads desolation

(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
Cached News: